TY  - JOUR
AU  - de Miguel-Luken, Maria Jose
AU  - Chaves-Conde, Manuel
AU  - Quintana, Begoña
AU  - Menoyo, Alicia
AU  - Tirado, Isabel
AU  - de Miguel-Luken, Verónica
AU  - Pachon, Jeronimo
AU  - Chinchon, David
AU  - Suarez, Vladimir
AU  - Carnero, Amancio
PY  - 2016
DO  - 10.18632/oncotarget.9172
UR  - http://hdl.handle.net/10668/10071
T2  - Oncotarget
AB  - Current larynx preservation treatments have achieved an improvement of laryngoesophageal dysfunction-free survival (LDS) but lead to significant toxicities and recurrences. At present, there is no evidence to select the group of patients that may...
LA  - en
KW  - DDR
KW  - H2AX
KW  - Pathology Section
KW  - biomarker
KW  - laryngeal cancer
KW  - laryngeal preservation
KW  - Antineoplastic Agents
KW  - Biomarkers, Tumor
KW  - Carcinoma, Squamous Cell
KW  - Chemoradiotherapy
KW  - Cisplatin
KW  - Disease Progression
KW  - Disease-Free Survival
KW  - Dose-Response Relationship, Drug
KW  - Female
KW  - Head and Neck Neoplasms
KW  - Histones
KW  - Humans
KW  - Kaplan-Meier Estimate
KW  - Ki-67 Antigen
KW  - Laryngeal Neoplasms
KW  - Male
KW  - Membrane Proteins
KW  - Middle Aged
KW  - Neoplasm Recurrence, Local
KW  - Phosphorylation
KW  - Predictive Value of Tests
KW  - Proportional Hazards Models
KW  - Retrospective Studies
KW  - Risk Factors
KW  - Squamous Cell Carcinoma of Head and Neck
KW  - Time Factors
KW  - Treatment Outcome
KW  - Tumor Suppressor Protein p53
TI  - Phosphorylation of gH2AX as a novel prognostic biomarker for laryngoesophageal dysfunction-free survival.
TY  - research article
VL  - 7
ER  -